A new treatment to improve glycemic control in Type 2 diabetes patients is making its debut from Sun Pharma.
Riomet ER (metformin hydrochloride for extended-release oral suspension) is the first and only liquid formulation of metformin.
The product is indicated as an adjunct to diet and exercise to improve glycemic control in patients 10 years of age and older with Type 2 diabetes mellitus.
Riomet ER is dosed once daily. It can be prepped and poured, thereby eliminating the need to crush the medication. The availability of a liquid formulation addresses the needs of patients with Type 2 diabetes mellitus, including residents in long-term care facilities, who often have issues swallowing solid medications. Riomet ER offers dosing flexibility and an acceptable taste, according to the company.
“As the fourth Sun Pharma product designed to address the needs of the 40% of U.S. adults who cannot or will not swallow solid medications, Riomet ER reflects our continued commitment to providing alternative formulations to underserved patient populations,” said Abhay Gandhi, Sun Pharma CEO, North America. “Our sprinkle and liquid formulation products treat common, chronic diseases – Type 2 diabetes, hypertension, elevated cholesterol, pain and depression – where adherence issues are common and can be life-threatening.”